Neuclare device for thinking skills in mild cognitive impairment or early Alzheimer's
Tests Neuclare device in mild cognitive impairment or early Alzheimer's.
Key facts
- Who runs it
- Deepsonbio
- Where
- Cheonan, Hwaseong-si, Incheon, Seongnam-si, Seoul, and Suwon, South KoreaSee the 7 sites
- Trial code
- Registry title
- Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease
- Status
- Recruiting
- People taking part
- 138 people, planned
- Started
- 20 Nov 2025
- Expected to end
- Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Participants receive Neuclare Device while continuing their cognitive medication
- Participants receive Sham Neuclare Device while continuing their cognitive medication
- Record updated
- 7 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 90 with mild cognitive impairment or very early Alzheimer's disease who already take memory medication. It tests a device for a short-term improvement in planning and problem-solving.
- Age
- 55 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Mild cognitive impairment or early Alzheimer's disease, with CDR 0.5-1 and MMSE-II ≥18.
- Earlier treatment
- Must have been on stable cognitive therapy medication for at least 1 month.
Main reasons for not taking part
- Structural brain lesions on brain MRI (for example bleeding, infarction, tumor)
- Uncontrolled metabolic disorders or long-term medicines that may cause cognitive impairment
- History of epileptic seizures, depression or psychiatric disorders
- Unable to undergo MRI
- Pregnant patients
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Adults aged 55 to 90 years
- Diagnosed with mild cognitive impairment (MCI) or early Alzheimer's disease according to the 2024 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria
- mild cognitive impairment/very mild Alzheimer's disease with CDR 0.5-1 and MMSE-II ≥18
- On stable cognitive therapy medications for at least 1 month
- Voluntary participation with signed informed consent
Who cannot take part
- Patients with a history of or currently taking psychoactive drugs or medications affecting the central or peripheral nervous system
- Patients with structural brain lesions detected on brain MRI (e.g., cerebral edema, intracerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.)
- Patients with uncontrolled metabolic disorders such as thyroid dysfunction, hypoglycemia, or hepatic/renal impairment, or those on long-term medications that may cause cognitive impairment (e.g., anticholinergic drugs)
- Patients with a history of epileptic seizures, depression, or psychiatric disorders; patients experiencing visual hallucinations or fluctuating cognitive decline
- Patients with psychiatric disorders outside of the inclusion criteria
- Patients with a history of severe diseases such as cancer or tuberculosis
- Patients with contact dermatitis or other skin hypersensitivity conditions
- Patients who have experienced bleeding within the past 3 months due to procedures or surgeries that may affect vital signs
- Patients with known allergies to contrast agents such as Definity or Gadovist
- Any other condition deemed by the investigator to make participation in the clinical trial inappropriate
- Patients with fever ≥ 40°C as measured by tympanic temperature
- Patients unable to undergo MRI
- Pregnant patients
- Patients with clinical brain calcification observed on computed tomography (CT) scans
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 90 years old?
Where in South Korea
- Soonchunhyang University Cheonan HospitalCheonan, South KoreaContact: Won Yi ChoTaking people
- Hallym University Dongtan Sacred Heart HospitalHwaseong-si, South KoreaContact: Ah Jeon YangTaking people
- Inha University HospitalIncheon, South KoreaContact: Joo Hye KwonTaking people
- Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Young Sook AhnTaking people
- Ewha Womans University Mokdong HospitalSeoul, South KoreaContact: Ji Suk LimTaking people
- Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Eun Kyung KimTaking people
- The Catholic University of Korea St. Vincent's HospitalSuwon, South KoreaContact: Hee Kyung HongTaking people
About the trial
What the trial wants to find out
This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and problem-solving abilities) in adults with mild cognitive impairment or very early Alzheimer's disease.
Read full original descriptionShow less
Participants will continue their current medication and be randomly assigned to receive either the Neuclare device (treatment group) or a sham device (control group). The device will be applied to the brain three times per week for four weeks. Both participants and study staff are blinded to the group assignment. Safety and adverse events will be closely monitored throughout the study.
During the trial, assessments will include attention, cognitive function, daily living activities, brain imaging (Amyloid PET-CT), blood biomarkers, and quality of life (EQ-5D-5L).
The goal of this study is to determine whether the Neuclare device, in combination with standard medication, can safely provide temporary improvements in executive function.
The 2 groups in the trial
- Neuclare DeviceTreatment being tested
Participants receive standard medication plus Neuclare device therapy three times per week for 4 weeks.
Treatment: Participants receive Neuclare Device while continuing their cognitive medication
- Sham DevicePlacebo, for comparison
Participants receive standard medication plus sham Neuclare device therapy.
Treatment: Participants receive Sham Neuclare Device while continuing their cognitive medication
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Randomized, Double-Blind, Parallel-Group, Confirmatory Clinical Trial to Verify the Efficacy and Safety of the Cognitive Improvement Effect on Executive Function in Medication-Treated Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease Using the Neuclare Physical Device for Medical Use
- Plain-language title
- Neuclare device for thinking skills in mild cognitive impairment or early Alzheimer'sGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07239310, who can take part
- Record updated
- 7 August 2026